Cantor Fitzgerald Forecasts NeuroPace FY2025 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for NeuroPace in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($0.79) for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.07. The company had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same quarter last year, the company earned ($0.28) earnings per share.

Other research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. boosted their price target on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. UBS Group began coverage on NeuroPace in a research report on Tuesday. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Wells Fargo & Company decreased their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, NeuroPace currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

NeuroPace Stock Performance

NeuroPace stock opened at $14.69 on Thursday. The firm’s fifty day moving average price is $11.34 and its 200 day moving average price is $8.61. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The company has a market capitalization of $438.50 million, a price-to-earnings ratio of -14.69 and a beta of 2.02. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.15.

Institutional Investors Weigh In On NeuroPace

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after purchasing an additional 6,181 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of NeuroPace during the second quarter worth $111,000. Financial Advocates Investment Management lifted its position in shares of NeuroPace by 20.0% in the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after buying an additional 3,000 shares during the last quarter. Barclays PLC lifted its position in shares of NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after buying an additional 16,007 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after buying an additional 8,643 shares during the period. 78.83% of the stock is currently owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.